Table 5.
Adjusted Cox proportional hazard model analyseswith 95% confidence interval for asthma hospitalization in children with asthma.
| Variables | Adjusted Hazard Ratioa | 95% Confidence Interval | p – Value |
|---|---|---|---|
| Gender | |||
| Males | reference | ||
| Females | 0.90 | 0.84–0.96 | |
| Age at diagnosis | |||
| 0–5 years | reference | ||
| 6–18 years | 0.66 | 0.59–0.74 | <0.0001 |
| Total number of comorbiditiesb | |||
| 1 | reference | ||
| 2 | 0.98 | 0.13–7.49 | |
| 3 | 1.30 | 0.18–9.29 | |
| 4 | 1.29 | 0.18–9.19 | |
| ≧5 | 1.45 | 0.20–10.35 | |
| Total number of asthma medicationc | |||
| 1 | reference | ||
| 2 | 1.70 | 1.04–2.77 | 0.0352 |
| 3 | 3.32 | 2.10–5.27 | <0.0001 |
| 4 | 5.05 | 3.20–7.95 | <0.0001 |
| ≧5 | 10.37 | 6.57–16.35 | <0.0001 |
| CHM usage | |||
| No(<30 days) | reference | ||
| Yes(≧30 days) | 0.90 | 0.83–0.95 | 0.0048 |
Abbreviations: CHM, Chinese herbal medicine.
adjusting all listed variables.
Comorbidities including:allergic rhinitis, acute upper respiratory infection, acute bronchitis, acute sinusitis, atopicdermatitis, gastroesophageal reflux disease, urticaria.
Asthma medication including:short-acting β2 agonists, short-acting anticholinergics, inhaled glucocorticosteroids,long-acting β2 agonists, antileukotriene, mast-cell stabilizers, anti-IgE monoclonal antibody.